Identification and validation of 12 immune‐related genes as a prognostic signature for colon adenocarcinoma

Abstract

Colon adenocarcinoma (COAD) is a common malignant tumor of the digestive tract that threatens human health seriously. Thus, it is urgent to explore biomarkers that can be used to evaluate a patient's survival prognosis overall as a supplementary treatment. RNA-seq expression profiles were downloaded from The Cancer Genome Atlas and Gene Expression Omnibus, and Lasso and multivariate Cox regression analyses were used for developing the prognostic model. Finally, a nomogram comprising the prognostic model was established to evaluate survival overall. A risk model comprised of a total of 12 immune-related gene pairs was constructed. Further analysis revealed the model's independent prognostic ability in relation to other clinical characteristics. This model's nomogram could help clinicians choose personalized treatment for COAD patients. This model has significant potential to complement COAD's clinical identifying characteristics, and also provide new insights into the identification of colon cancer patients with a high risk of death.

Correlation analysis of PBX family with immune invasion and drug sensitivity in colon adenocarcinoma

“…Colon cancer is one of the most common cancers in the world, especially in the late stage, it is prone to the problem of chemotherapy resistance, and the recurrence rate is high [ 10 ]. COAD is a common pathological type of colon cancer and a common digestive tract tumor, and it not only poses a great threat to the lives of patients, but also causes a huge economic burden to society and families [ 11 ]. After distant metastasis of COAD, the mortality of patients will increase significantly [ 12 ].…”